SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Semisynthetic Synthesis of Mutacin 1140
Award last edited on: 4/20/2021

Sponsored Program
SBIR
Awarding Agency
NSF
Total Award Amount
$100,000
Award Phase
1
Solicitation Topic Code
-----
Principal Investigator
Jeffrey D Hillman

Company Information

Oragenics Inc (AKA: Oragen Inc~Oragenics Inc~ONI Biopharma Inc)

4902 Eisenhower Boulevard Suite 125
Tampa, FL 33634
   (813) 286-7900
   info@oragenics.com
   www.oragenics.com
Location: Single
Congr. District: 14
County: Hillsborough

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2004
Phase I Amount
$100,000
This Small Business Innovation Research (SBIR) Phase I project will develop new preparative strategies for the peptide antibiotic Mutacin 1140 and related derivatives. Current fermentation and synthetic routes are impractical. In-vitro testing suggests that Mutacin and its derivatives may work on drug-resistant bacterial strains. The peptide backbone of the antibiotic will be produced by cloning and expressing a 22mer artificial gene. The structure will then be modified to a range of derivatives synthetically. The commercial application of the proposed project is in the area of antibiotics to combat human infectious diseases. Screening has indicated effectiveness against a wide range of gram positive and some gram-negative pathogens including multidrug resistant strains of Staphylococcus aureus

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----